Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

INTRODUCTION: Concomitant use of ledipasvir and boosted protease inhibitors (PIs) may increase the risk of tenofovir (TDF) nephrotoxicity, since both these drugs increase TDF levels. Our aim was to evaluate glomerular filtration rate (eGFR) evolution during HCV treatment with sofosbuvir/ledipasvir (...

Descripción completa

Detalles Bibliográficos
Autores principales: Soeiro, Cristina Aurora São Pedro, Gonçalves, Celina Andreia Melo, Marques, Marta Sofia Correia, Méndez, Maria Josefina Vazquez, Tavares, Ana Paula Ribeiro Almeida, Horta, Ana Maria Lacerda Morgado Fernandes de Carvalho de Aboim, Sarmento-Castro, Rui Manuel do Rosário
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090809/
https://www.ncbi.nlm.nih.gov/pubmed/30075765
http://dx.doi.org/10.1186/s12879-018-3278-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090809/
https://www.ncbi.nlm.nih.gov/pubmed/30075765
http://dx.doi.org/10.1186/s12879-018-3278-3

Ejemplares similares